ABSTRACT Cardiovascular (CV) 
Introduction
the progress in the discovery of new molecules and medicinal products acting on the cardiovascular (cV) system has increased their utilization all over the world in the last 20 years, with a market share of approximately 10% world wide (2, 10, 30, 42) .
the cardiovascular medicines are of particular interest as cardiovascular diseases are the leading cause of mortality and morbidity worldwide (40) . Bulgaria is not an exception. the age-standardized mortality rate for cardiovascular diseases is 554.0 per 100,000 in the Bulgarian population (24) . Moreover, hypertension is another leading cause of death (108.1 per 100,000) (13) .
Studying drug utilization by using the defined daily doses consumed by 1000 inhabitants per day (DDD/tiD) contributes to the evaluation of rational use of medicines and assessment of the factors influencing the process (1, 41) .
cV medicines are also among the most commonly prescribed reimbursement pharmaceuticals. (29) . they are targeted by the pharmaceutical manufacturers concerning active development and marketing, and are also of interest to the health insurance authorities in connection with costcontainment measures (13, 14, 28) .
Various aspects of the utilization of cV medicines have previously been explored in studies both at national level and as part of international comparisons (37) . there are a limited number of studies, showing the increase in utilization and changes in the costs of cV medicines in the reimbursement practice, presented in mg after the introduction of generic versions of medicines (4, 17) . Another work shows a rapid decrease in costs per DDD after patent expiry of the originator product and generic appearance (3) . Some studies generally focus on the effects of generics and their possible influence on the prescription of medicines, the utilization of original medicinal products, as well as the cost-savings from the perspective of the reimbursement system (7, 23) . the introduction of a new generic can also influence the utilization not only of the originator, but also of the other therapeutic molecules, considered as therapeutic competitors within the same pharmacological group (6) .
Studies of the changes in medicines utilization and prices in DDD after the introduction of new generic molecules or
UTILIZATION AND PRICE TRENDS IN SOME REIMBURSED CARDIOVASCULAR MEDICINES
therapeutic competitors are of particular interest in the countries where the DDD are used for reimbursement purposes.
in Bulgaria the obligatory health insurance system was established in 1998 after the endorsement of the first Health insurance Act (27) . the reimbursement was based on a list of fully or partially paid medicines. In 2003, for the first time in Bulgaria a Positive Drug list (PDl) was introduced for reimbursement of all medicines paid by public financial sources such as the Ministry of health budget, Municipality budgets, national health insurance funds, and hospitals (19) . the PDl became obligatory for the above mentioned institutions. Since 2004 Bulgaria has had the reference price system changed twice. the reference price is an element of the reimbursement price (21, 22) . it is the lowest price for the same medicinal product in eight reference countries, calculated and updated annually on the basis of information provided by the marketing authorisation holder. Since 2008 the cost that the national health insurance Fund (nhiF) pays for each trade name is calculated by multiplying the quantity of the active ingredient within it by the lowest price per DDD and determining the level of co-payment (20) . the co-payment rates are productspecific, and do not differ depending on patient groups. For medicines paid by the Ministry of health (Moh) and hospitals no co-payment exists. their prices are subject to tender negotiation within the framework of the reference prices at wholesale level.
After the introduction of the DDD as a measure not only of the medicines utilization, but also of their reimbursed price level setting, no particular study analyzes the changes in the prescribing policy and cV medicines prices. this is especially the case in Bulgaria where only one study has been published exploring the impact of changes in prices and utilization in milligram of active, whereas this study focuses on the changes in utilization and prices measured in DDD.
the aim of this study was to analyze the changes in utilization, measured in DDD/tiD and prices of 3 groups of reimbursed cardiovascular medicines in Bulgaria (Ace inhibitors, hMG-coA reductase inhibitors and inhibitors of At-receptors) during 2005-2007 in respect of the introduction of generics or therapeutic competitors in the reimbursement list.
the point of view was that of the reimbursement system and the main question addressed was: "Did the introduction of new generics or therapeutic competitors within the observed cardiovascular groups of medicines lead to the changes in utilization measured in DDD/tiD and prices?"
Materials and Methods
the medicines included in the study are present in the Positive Drug list and are reimbursed by the nhiF.
the study period covered the years 2005 -2007 . Prescribing data for the observed medicines was derived from the official database of the national health insurance Fund (nhiF). the access to nhiF database was authorised by the institution in 2008. Seven inn Ace inhibitors, six hMG-coA reductase inhibitors (statins) and five inhibitors of AT-receptors (sartans), authorized for sale on the Bulgarian market and reimbursed by the nhiF were included. the database for the prescribed packages comprised of 86 to 92 dosage forms of medicinal products sold under the observed 18 inn during the period.
the data on the prescription of the different medicinal products was systematized by inn, and was recalculated in utilized milligrams for all the packages under the same inn. then the utilization in mg was converted in DDD/tiD for every inn and within the therapeutic group following the methodology of the World health organisation (Who) (39 the DDD for every included inn was taken from the official database of the NHIF in 2009 due to the fact that this was the officially used DDD by the institution and then compared with the latest version of Atc DDD system for consistency (33) . No differences in the DDD were matched. The fixed dose combinations were not included in the analysis due to the fact that they were no reimbursed during the observed period. the utilization in DDD/tiD was analyzed product by product and within the drug classes in relation to the availability of generics. to analyze the price changes for every medicinal product in a given period, the national health insurance Fund's retail price per DDD for every dosage form in national currency was calculated (26). then a descriptive statistic analysis was performed and the mean price per DDD per inn was taken into account. t-test analysis, assuming 95% ci, was performed for the changes in mean prices per DDD of inn comparing changes in 2006 and 2005, in 2007 and 2006, and in 2007 and 2005 . the sample size was determined by the number of dosage forms under the same inn. in the group of sartanes the mean price was calculated and compared for all inns in the group considering them as therapeutic competitors and comparing them. the t-test provides information for the statistically significant differences in the mean prices per DDD in the aforementioned years.
Results and Discussion
out of all the observed medicinal products in the class of Ace inhibitors, generic competitors were observed only for three inns. these were for enalapril, lisinopril and for ramipril included in 2007. in the class of statins four inns have generics (simvastatin, lovastatin, pravastatin, and atorvastatin for 2006 Table  1) . the other inns within the studied therapeutic groups were considered as therapeutic competitors without generic versions. new therapeutic competitors were included in the reimbursement list during the observed period in the group of Ace inhibitors -cilasapril and benazepril. in the group of statins rosuvastatin was included, and irbesartan was dropped out of the sartans group in 2007 ( Table 1) .
Trends in price changes in the group of Ace inhibitors the mean prices per DDD for lisinopril and trandolapril decreased during the three-year period, while for enalapril, during the first two years, the price decreased and then increased, but the number of reimbursed dosage forms decreased. For the other products within the group small deviations in mean prices were observed but all were not statistically significant ( Table 1) . in the group of statins mean prices of simvastatin and atorvastatin permanently decreased, three fold for simvastatin. After the introduction of three new dosage forms, this change appears to be statistically significant comparing 2007 and 2005. Pravastatin mean price decreased almost 4 times in 2007 but the changes were not statistically significant. Prices remained unchanged for fluvastatin and rosuvastatin, and no competitors entered the reimbursement list ( Table 1) .
the sartanes' mean price for the whole group decreased, but the number of dosage forms also decreased and thus the change in prices per DDD was not statistically significant.
Trends in CV medicines utilization
For the group of ACE inhibitors the product which ranked first according to prescription and generic entry was enalapril. We evaluated 42 different dosage forms, representing 11 trade names, for inn enalapril. Utilization of the different forms of enalapril was significantly higher than that of the forms of the other studied Ace inhibitors and continued increasing during the observed years (67.68 -81.60 -84.70 DDD/tiD), probably due to the fact that the medicines belonging to the group were well established on the market and possessed the lowest prices of the generics (Fig. 1) . it is necessary to point out that the utilization of enalapril in DDD/tiD increased markedly in the second year when five new generics were included in nine dosage forms, and this tendency has continued, despite the decreasing number of the population ( Table  2) . the second product within the class is ramipril, whose utilization increased from 0.83 to 7.91 DDD/tiD at the end of period after the introduction of new generic version ( Table  2) . Similar tendencies have been observed for lisinopril after the introduction of a new product that changed the utilization from 1.7 to 5.55 DDD/tiD. For the rest of the Ace inhibitors no new products were added but their utilization also showed an increase that could be due to their rising prescription and corresponding to the overall increasing morbidity. Another possible reason could be the fact that Ace inhibitors are recommended by the therapeutic guidelines. quinapril is the only product, the utilization of which decreased in 2007 in comparison to 2005 . For all representatives from this therapeutic group of Ace inhibitors the changes in utilization, measured in milligrams and in DDD/tiD, were statistically significant (p<0.05) during the period ( During the three-year period in the statins' group of medicines we have found an increase in the consumption of all products (except fluvastatin) and a slow decrease for lovastatin in the third year. two generic simvastatin products were introduced in 2006, which reflected the utilization in the period 2006 -2007, increasing to 1.5 DDD/tiD. After the inclusion of two new generic products in 2006 lovastatin also markedly increased its utilization from 1.57 to 2.47 DDD/tiD (Fig. 2) Diverse trends were observed for the third studied group of cV medicines -sartans (Fig. 3, Table 2 ). In the first and second year the utilization of telmisartan in DDD/tiD was the highest, while in 2007 the utilization of losartan sharply increased (from 0.11 to 1.40 and to 3.48 DDD/tiD). only losartan had generic versions during the first year of the observed period. Valsartan consumption was stable during the studied period while eprosartan and irbesartan had the smallest values for DDD/tiD. the changes in the drug utilization measured in DDD/TID were not statistically significant ( Table 2 ).
All therapeutic groups performed an increase in the total utilization measured in DDD/tiD for the observed period ( Table 2) . the total utilization of Ace inhibitors increased from 73.76 to 95.55, and to 137.7 DDD/tiD. For the group of statins the total utilization increased from 2.57 to 3.96, and to 5.26 DDD/tiD, while in the groups of sartanes it increased from 1.89 to 3.81 and to 5. the introduction of new molecules and rapid generic penetration allows reimbursement institutions to drive prices down, but our study has not provided any statistically supported evidence of that. A lot of contemporary cV medicines in the reimbursement list were analyzed in our study in relation to their therapeutic and market attractiveness, and morbidity patterns. the increasing utilization of the medicines from all three groups could be explained with the high prevalence of cardiovascular diseases among the Bulgarian population (25). This increase is statistically significant and it is mostly evident for the inns where there is a generic version such as enalapril, ramipril, lisinopril, simvastatin, lovastatin and atorvastatin. thus we can conclude that the introduction or availability of generic competitors lead to increase in the utilization of the same INN. It seems that the introduction of generics benefits both the originator and the generic versions.
the consumption of Ace inhibitors in DDD/tiD is almost twice as high as the average figures provided for the Nordic countries in 2002. More recent studies comparing the Ace inhibitors and sartanes in Sweden have found that the Ace inhibitor utilization is 62.3 DDD/tiD as a whole which is lower than our figures, while the sartanes usage is extremely higher (38.8) (9). These figures should be commented with caution because other studies show that when the sartanes utilization decreased due to regulatory measures the Ace inhibitors utilization rose up (38) . the statins usage in Bulgaria is much lower than the international variables (32) . Studies from other central european countries report similar results for Ace inhibitors, where enalapril utilization changed from 78.6 DDD/tiD in 2005 and 88.6 in 2007 (37) . the total reported utilization of Ace inhibitors is a little higher 148.8 DDD/tiD in 2007 in comparison with Bulgaria but sartanes have not been considered in this study (37) . A variety of factors might influence the utilization patterns. First, it could be the introduction of the generic medicines, which are less expensive than the original medicinal products with the essentially similar efficacy and safety (8, 11, 16, 34) . Second, it could be the changes in the relevant professional and health management guidelines, as is the case for the changes in the hypertension guideline, where the Ace inhibitors have been recommended 'first-line use' in hypertensive patients aged less than 55 years (5, 31) . our study showed that the introduction of a new generic changes the utilization of the well-established molecules with more generic versions on the market. the differences in utilization patterns could be explained by the existing prescription habits and/or marketing policy of the pharmaceutical companies. it is evident from our study that the utilization of Ace inhibitors showed a steady and permanent increase during the studied period, matching the morbidity figures. The same was the tendency for statins and sartanes. the inclusion of a new generics is possible only for molecules with expired patents which could explain the high number of generics for well established molecules such as enalapril, simvastatin etc. and it is also evident from our study that the increase in the utilization of these molecules was statistically significant.
the marketing policy also affects utilization. Such a presumption is supported by the fact that in Bulgaria the leader in the group of statins was lovastatin, while in the other countries it is simvastatin. this is due to the premium price that the pharmaceutical company established after the inclusion of lovastatin marketing the reimbursement list. After the introduction of new simvastatin with lower prices in 2007, the usage of the whole inn started to increase. So it could be supposed that the market is price sensitive. For some of the medicines like simvastatin the mean price decreased almost 3-fold and this led to the sharp increase in usage that confirms the assumption about the influence of competitors on the prices and usage. it is also necessary to bear in mind that the DDD for statins almost doubled in 2009 and this could affect the results by decreasing the utilization in DDD/tiD, but the general tendency of increasing statins utilization would probably remain.
Despite the opinion that generics create competition and drive medicines prices down, we did not find such evidence (12, 15, 18, 35, 36) . our study did not show statistically significant changes in the mean prices of the observed medicines, except for one product. this result could be explained in many ways. First, the smaller sample size determined by the number of observed dosage forms, as well as the shorter period of observation could influence this result. Second, the reimbursement policy also affects the prices and the sample size because not all products with the same inn were immediately included in the reimbursed list during the observed period and thus the observation of the price effect was difficult at the moment of the competitors' entrance.
the positive drug list committee (PDlc) updated the list only once a year and this practice has now changed due to the new regulation (19) . the PDlc should gather on a regular basis and discuss new medicines entry permanently. the marketing authorization holders apply both for inclusion of their medicines in the PDl and for price setting for reimbursement purposes. the new regulation endorsed a new methodology after 2008 for the establishment of the reimbursement level on the basis of the lower price per DDD in eight reference health insurance funds in other countries. After the price setting the committee calculates the lowest price per DDD and establishes it as the reimbursement level paid 100% by the health insurance Fund. Patient co-payment is added up to that price for the rest of the products. thus the new generic medicines which have a lower price per DDD will be fully reimbursed. it is expected that such a practice should benefit the generics entrance on the market.
it could be expected that in the future the consumption in DDD/TID will increase (20) . To match the significance in price changes per DDD further analysis should be done after the endorsement of the new regulation, as well as for a longer period and for more products.
Actually our study was developed with the main purpose to add more evidence during the period of new regulations development and professionals' discussions. this study is the second part of the analysis of the impact of generic competition for market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market (17) . In the first part the generic influence on the usage and prices presented in mg of active substances was evaluated, which was the reimbursement methodology at that time. the current analysis explores the influence of the generics on usage and price but measured in DDD and DDD/tiD, which is more clinically relevant.
the main factor affecting the medicines utilization is morbidity. in addition, for Bulgaria the ageing of the population seems to have a greater influence, and legislation changes. Marketing policy of manufacturers in terms of new molecules or generics development could change the internal structure of the medicines utilization but could not change the main tendency, which was confirmed by our study.
As the first Bulgarian study that is applying the DDD methodology for the cV medicines in the reimbursement practice this study has some limitations such as the lack of information about the consumption of the inns out of the positive drug list, as well as about the combination products that were also out of the list but have an important effect on the cardiovascular disease therapy. it also focuses on a particular time period and lacks an analysis of the sequence of events and their impact due to the limited information from the health insurance Fund database. the Bulgarian health insurance Fund was created in 1998 and reimbursement started in 1999. Until 2007 the list of medicines was changed mainly by inclusion of new medicines. in 2008 a substantial change in the reimbursement policy was made with the introduction of DDD for reimbursement purposes that aroused our interest. Further studies need to be done to explore the sequence of events and their impact, for example, the entry of generics and its impact on the price of brands, or reimbursement status changes and their impact on the price of brands, etc.
We also acknowledge the limits of the existing reimbursement drug policy in the country, which does not employ most of the recommended measures for cost containment, oriented towards generics and supports generic competition by the introduction of the prescribing budgets, generic substitution, and information campaigns (28) . Actually our study shows that it is not enough only to introduce a reference pricing system and to decrease the prices. other important factors might be the number of reimbursed products, the number of generic competitors etc. it appears that a period longer than three years is necessary to benefit by generic competition.
Conclusions
In general our study confirms the similar analyses of the generics' penetration influence on the prices and utilization of medicines with the same inn and within the therapeutic group. It also adds more evidence about the important influence of the new therapeutic molecules, especially on the relatively new pharmacological groups as sartans.
We do observe a dynamic utilization of cV medicines that corresponds to the world tendencies.
We can recommend to the national health insurance authorities to develop regulatory measures for faster uptake and price competition among generics in the positive drug lists because it will influence the utilization, as well as the affordability of pharmaceuticals.
